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Abstract
Background: The ACT recommended by WHO is very effective and well-tolerated. However, these combinations
need to be administered for three days, which may limit adherence to treatment.
The combination of dihydroartemisinin - piperaquine phosphate - trimethoprim (Artecom
®, Odypharm Ltd), which
involves treatment over two days, appears to be a good alternative, particularly in malaria-endemic areas. This
study intends to compare the efficacy and tolerability of the combination dihydroartemisinin - piperaquine
phosphate - trimethoprim (DPT) versus artemether - lumefantrine (AL) in the treatment of uncomplicated
Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal.
Methods: This was a randomized, controlled, open-label clinical trial with a 28-day follow-up period comparing
DPT to AL as the reference drug. The study involved patients of at least two years of age, suffering from acute,
uncomplicated Plasmodium falciparum malaria with fever. The WHO 2003 protocol was used.
Results: A total of 418 patients were included in the study and divided into two treatment groups: 212 in the DPT
group and 206 in the AL group. The data analysis involved the 403 subjects who correctly followed the protocol
(per protocol analysis), i.e. 206 (51.1%) in the DPT group and 197 (48.9%) in the AL group. The recovery rate at D14
was 100% in both treatment groups. The recovery rate at D28 was 99% in the DPT and AL groups before and after
PCR results with one-sided 97.5% Confidence Interval of the rates difference > -1.90%. More than 96% of patients
who received DPT were apyrexial 48 hours after treatment compared to 83.5% in the AL group (p < 0.001). More
than 95% of the people in the DPT group had a parasite clearance time of 48 hours or less compared to
approximately 90% in the AL group (p = 0.023). Both drugs were well tolerated. No serious adverse events were
reported during the follow-up period. All of the adverse events observed were minor and did not result in the
treatment being stopped in either treatment group. The main minor adverse events reported were vomiting,
abdominal pain and pruritus.
Conclusion: The overall efficacy and tolerability of DPT are similar to those of AL. The ease of taking DPT and its
short treatment course (two days) may help to improve adherence to treatment. Taken together, these findings
make this medicinal product a treatment of choice for the effective management of malaria in Africa.
* Correspondence: rvmenan@yahoo.fr
1Department of Parasitology, Faculty of Pharmacy, University of Cocody,
Abidjan, Côte d’Ivoire
Full list of author information is available at the end of the article
Menan et al. Malaria Journal 2011, 10:185
http://www.malariajournal.com/content/10/1/185
© 2011 Menan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
The use of artemisinin-based combination therapy (ACT)
is one of the strategies recommended by the WHO to
effectively combat chemoresistance of strains of Plasmo-
dium [1]. Artemisinins rapidly and effectively reduce the
parasite biomass. In addition, very few documented cases
of resistance to these compounds have been reported [2].
Because of their short half-life time, however, cases of
parasite reinfection have occurred during their use in
monotherapy to treat malaria. This also carries a risk of
selecting chemoresistant strains of Plasmodium. Artemisi-
nins need, therefore, to be associated with effective anti-
malarials which have a relatively long half-life time. Not all
combinations are good alternatives. This applies to the
combination of artesunate/sulphadoxine-pyrimethamine
(SP) because of the relatively limited effectiveness of SP in
monotherapy [3,4] and this combination is not recom-
mended in areas where the SP cure rate is under 80% [1].
In contrast, the combinations artesunate-mefloquine and
artesunate-amodiaquine are highly effective, although they
have disadvantages associated with their co-administration
and tolerability.
The fixed-dose ACT artemether-lumefantrine (Coar-
tem
®) remains very effective and well tolerated. It is
recommended, however, that it be administered twice
daily for three days with a fat-rich meal, which may limit
adherence to treatment. In this context, the combination
of dihydroartemisinin - piperaquine phosphate - trimetho-
prim (Artecom
®, Odypharm Ltd), which involves treat-
ment over two days, appears to be a good alternative,
particularly in malaria-endemic areas. This triple combina-
tion may also be a response to the reduced efficacy of dual
ACT therapy that has already been seen in several Asian
countries [5-9] and also a useful alternative in the face of
increased selection of strains of Plasmodium resistant to
the partner molecule of artemisinin in the combination
[10]. No investigation had yet been conducted in Africa
into the effectiveness and tolerability of Artecom
®.
This study therefore intends to compare the efficacy
and tolerability of the combination dihydroartemisinin -
piperaquine phosphate - trimethoprim (DPT) versus
artemether - lumefantrine (AL) in the treatment of
uncomplicated Plasmodium falciparum malaria in
Cameroon, Ivory Coast and Senegal.
Methods
Study sites
The study was conducted from September 2008 to Feb-
ruary 2009 in three sub-Saharan African countries.
Cameroon is located in central equatorial Africa and has
a western sea front. Malaria is transmitted intensely in
this country throughout the year, as it is in Ivory Coast,
which occupies a central position in the Gulf of Guinea.
In Senegal, located in the extreme west with its
northern part on the edge of the Sahel and a western
sea front, malarial transmission is seasonal with a peak
between September and December.
Study population
The study considered patients at least two years old suf-
fering from acute, uncomplicated Plasmodium falci-
parum malaria with fever (axillary temperature ≥37.5°C)
and a parasitaemia of between 1,000 and 100,000 tropho-
zoites/μl in Senegal and 2,000 to 200,000 trophozoites/μl
in Cameroon and Ivory Coast. Patients with signs of
complicated malaria, severe malnutrition, repeated
vomiting, intercurrent infectious disease, known allergy
to the study drugs, past cardiac, hepatic or renal history
or who were pregnant (positive test) or breast-feeding,
were excluded.
Before inclusion, written informed consent was
obtained from the patient or the patient’s legal guardian.
Approval was obtained from the national ethics commit-
tees in the three countries before the study was started.
An insurance contract was also taken out in view of the
possibility of serious adverse events.
Study procedures
This was a randomized, controlled, open-label clinical
trial with a 28-day follow-up period comparing DPT to
AL as the reference drug. The WHO 2003 protocol was
used [11]. Patients who were enrolled were weighed and
randomized into each arm, either DPT or AL. In each
study site computer generated randomization codes were
prepared by an independent individual without the use of
blocking. These codes were enclosed in sequentially
numbered opaque sealed envelopes, each of which con-
tained the treatment allocation. The envelopes were
assigned in sequential order to participants after inclu-
sion. The number of patients to be enrolled was deter-
mined by Epi Info 2000 software. The estimated expected
recovery rate with AL was 98%, with a maximum accep-
t a b l ed i f f e r e n c eo f5 %t oc o n c l u d et h a tD P Tw a sn o n -
inferior and a power of 85%. The minimum number of
people to be included in each arm was calculated from
these assumptions to be 180 patients. Assuming a 10%
loss to follow up the overall final target sample size of
400 participants was estimated.
DPT is presented in the form of tablets containing
32 mg of dihydroartemisinin, 320 mg of piperaquine
phosphate and 90 mg of trimethoprim. The dose, which
is administered in two divided daily doses, varies depend-
ing on patient weight: half a tablet mornings and eve-
nings for two days from 10 to 19 kg, one tablet mornings
a n de v e n i n g sf o rt w od a y sf r o m2 0t o2 9k g ,o n ea n da
half tablet mornings and evenings for two days from
30 to 39 kg, and two tablets mornings and evenings for
two days over 40 kg.
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of artemether and 120 mg of lumefantrine. This drug is
also administered depending on the patient’sw e i g h to n
T0, T8, T24, T36, T48 and T60 h.
All of the daily doses were taken in the health centre
with the assistance of a co-investigator. If the patient vom-
ited within thirty minutes after the drug was administered,
the whole dose was re-administered. If the vomiting per-
sisted, the patient was excluded from the study and
referred to the health centre doctor for management
according to the current national policy. The dose could
not be administered again if vomiting occurred more than
60 minutes after administration. If the patient could not
tolerate the study drug or if his/her medical condition
deteriorated, he/she was required to stop the treatment.
The same approach was used for treatment failures. In
this situation, a standard replacement anti-malarial ther-
apy (quinine salts) was to be administered and recorded in
the case report form. The patient was to continue being
followed up, in line with the schedule.
Patients were examined clinically on D1, D2, D3, D7,
D14, D21 and D28 after inclusion and thick and thin
blood films were performed at each visit. The density of
P. falciparum in the peripheral blood was determined by
counting the number of asexual parasites in 200 white
blood cells (WBC). All of thick and thin blood films were
reread to double check. Haematological (full blood count)
and biochemical (creatinine, transaminases and bilirubin)
investigations were performed on D1 and D7. Genetic pro-
files for markers of the MSP1 and MSP2 polymorphisms
were studied if the parasitaemia re-emerged as of D7 dur-
ing the patient’s follow-up, in order to distinguish reinfec-
tion from parasite recrudescence.
End points
The primary end point was the recovery rate, defined as
the percentage of patients who had an adequate clinical
and parasitological response (ACPR) after follow-up for
28 days. Efficacy was evaluated using an intention to
treat analysis which included all the 418 randomized
patients then using a per protocol analysis which
included the 403 patients who completed 28 days follow-
up. The secondary end points were the incidence of early
clinical failure (ECF), late parasitological failure (LPF),
late clinical failure (LCF), change in gametocyte carrier
status, abolition of fever and parasites and adverse clini-
cal and laboratory events.
Data analysis
Data were registered in Epi data version 3.1 software. The
statistical analysis was carried out on Spss 12.0 software
for windows. Demographic, clinical and laboratory para-
meters of the two groups at inclusion were compared
using the t test for independent samples or Mann-
Whitney test. A pure intention to treat analysis was per-
formed using Kaplan-Meier survival analysis with log
rank testing the treatment failures distribution function.
Then, per protocol recovery rates were estimated and
comparison of treatment efficacy was made using rates
difference with one-sided 97.5% confidence interval. Fish-
er’s exact test was used where appropriate. The distribu-
tions of fever and parasite clearance were compared
using Pearson’s Chi-2 test. Differences of haematological
and biochemical parameters values within individuals
between D1 and D7 were computed. Changes in haemo-
globin concentrations and in other laboratory tolerability
parameters were compared using the paired t test. The
level of significance for statistical tests was set at 0.05.
Results
Global distribution of patients in the study
A total of 418 patients were included in the study and
divided into two treatment groups: 212 in the DPT group
and 206 in the AL group. The protocol was discontinued
in 15 cases during the follow-up period, six in the DPT
group and nine in the AL group (1 patient lost to follow-
up, 3 withdrawals of consent and 2 refusals of blood draws
in the DPT group and 7 patients lost to follow-up, 1 with-
drawal of consent and 1 refusal of blood draws in the AL
group). The study profile and distribution of patients in
each treatment group and number of patients who under-
went full follow-up are summarized in Figure 1. The data
analysis involved the 403 subjects who correctly followed
the protocol (per protocol analysis), i.e. 206 (51.1%) in the
DPT group and 197 (48.9%) in the AL group.
Demographic, fever, laboratory and clinical features of
the patients in each arm
The demographic, fever, laboratory and clinical features
of the patients are summarized in Tables 1 and 2 by
treatment group. There were no statistically significant
differences in distribution by sex or age band. Average
temperatures in the two treatment groups were not sta-
tistically different. There were also no statistically signifi-
cant differences between any of the laboratory
parameters. Both groups were therefore statistically
equivalent at inclusion.
The median daily doses of the molecules were 2.5 mg/kg
[1.4-4.7] for dihydroartemisinin, 7.1 mg/kg [3.8-13.3]
for trimetoprime and 25.1 mg/kg [13.5-47.4] for pipera-
quine. They were 3.5 mg/kg [1.2-5.3] for artemether and
20.1 mg/kg [7.0-32.0] for lumefantrine.
Efficacy of treatment
Kaplan-Meier estimates of recovery rates unadjusted by
genotyping were 96.2% in the DPT group and 95.6% in
the AL group. There was no statistical difference between
the two groups (p = 0.755). The per protocol recovery
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recovery rate [95% CI] at D28 was 99.0 [96.2 - 99.8]% in
the DPT group and 99.0 [96.0 - 99.8]% in the AL group.
These results are shown in Table 3. The rates difference
was 0.04%, 97.5% CI > -1.90%.
Two cases of late parasitological failure (LPF) were
seen in two patients in the DPT group at Day 28. Two
cases of failure including one early treatment failure
(ETF) at Day 4 and one late clinical failure (LCF) at Day
28 were seen in the AL group. PCR results confirmed
the LPF and LCF. These were cases of parasitological
recrudescence and not reinfection. The difference in
response to treatment between the two groups was not
statistically significant.
Parasite clearance and abolition of fever
Fever was abolished within 24 hours in the majority of
patients in both treatment groups. More than 96%
(188/195) of patients who received DPT had no fever
48 hours after treatment compared to 83.5% (152/182)
in the AL group. The difference between the distribu-
tion of times to abolish fever between the two groups
was statistically significant (p < 0.001 Pearson’sC h i - 2
test).
More than 96% (198/206) of the people in the DPT
group had a parasite clearance time of 48 hours or less
compared to approximately 90% (177/197) in the AL
group. The difference in distributions of times to
achieve parasite clearance between the two groups was
statistically significant (p = 0.023, Pearson’s Chi-2 test).
These features are summarized in Figures 2 and 3.
Change in gametocyte carrier status
At inclusion, there were only three gametocyte carriers
in the DPT group and none in the AL group. The num-
ber of gametocyte carriers fell to two on D2 and one on
D 3i nt h eD P Tg r o u p .F r o mD 7t h e r ew e r en om o r e
gametocyte carriers in this group. There were no
patients who developed gametocytaemia after inclusion.
Change in haemoglobin from D1 to D7
Examination of haemoglobin concentrations revealed a
fall of individuals’ values within the seven days after
starting the study treatment. This fall in each of the two
treatment groups was statistically significant (p < 0.001),
as presented in Table 4. The fall of individuals’ haemo-
globin values summarized as mean of differences was
greater in the AL group (1.0 g/dl) than in the DPT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Study profile showing the number of patients recruited into each arm.
Menan et al. Malaria Journal 2011, 10:185
http://www.malariajournal.com/content/10/1/185
Page 4 of 8group (0.7 g/dl), p = 0.024. There were no statistical dif-
ference between study sites.
Assessment of tolerability of DPT versus AL
Both drugs were therefore well tolerated and no serious
adverse events were reported during the follow-up per-
iod. All of the adverse events observed were minor and
did not result in the treatment being stopped in either
treatment group. Ten cases of vomiting within 30 min-
utes were observed after administration of DPT and 13
cases after administration of AL also within 30 minutes.
The whole dose was re-administered in each case.
The number of patients who experienced at least one
adverse event in the DPT group, 47 (22.8%), was higher
than those, 29 (14.7%), in the AL group, p = 0.038. 50
cases of adverse events were reported in the DPT group
and 31 in the AL group (Table 5). The main adverse
events reported were vomiting, abdominal pain and pruri-
tus. It looks that vomiting was significantly more frequent
in DPT group (10%) than AL group (3%), p = 0.004. The
most of the adverse events after DPT were gastrointestinal.
These side effects occurred more often in children than in
adults.
In terms of laboratory tolerability, individuals’ values
of transaminases fell in the DPT group whereas they
rose in the AL group between the start of the study
treatment and day seven. These differences, however,
were not statistically significant. Similarly, serum creati-
nine fell between the start of treatment and day seven
in the DPT group but rose in the AL group. The differ-
ences found in each group for this parameter, however,
were not statistically significant. The fall in individuals’
values of bilirubin between the start of the study treat-
ment and day seven was statistically significant in both
treatment groups but no statistical difference was found
between treatment groups (Table 6).
Discussion
In this study conducted in Cameroon, Ivory Coast and
Senegal the two medicinal products, DPT and AL, were
Table 1 Comparison of the two treatment groups at
inclusion
DPT AL p*
Numbers 206 197
Sex M, n (%) 97 (47.1) 93 (47.2) 0.921
F, n (%) 109 (52.9) 104 (52.8)
Mean age (SD) years 15.51 (12.64) 15.58 (11.91) 0.958
Min - Max 2-6 0 2-6 2
[2 - 5], n (%) 36 (17.5) 30 (15.2)
[5 - 15], n (%) 87 (42.2) 85 (43.1)
[15-62], n (%) 83 (40.3) 82 (41.6)
Mean temperature (SD) °C 38.73 (0.96) 38.58 (1.03) 0.134
Min - Max 35.5 - 41.0 35.2 - 41.4
< 37.5, n (%) 11 (5.3) 15 (7.6)
[37.5 - 38.5], n (%) 63 (30.6) 77 (39.1)
[38.5 - 41.4], n (%) 132 (64.1) 105 (53.3)
Median parasitaemia tpz/μl 13225 13400 0.934**
Min - Max 1000 -
255000
1040 -
187500
Gametocyte carrier rate, n
(%)
3 (1.5) 0 (0) 0.249§
Mean ASAT (SD) IU/l 30.59 (21.71) 31.36 (18.99) 0.705
Min - Max 5-165 7-134
Mean ALAT (SD) IU/l 25.9 (20.61) 27.98 (16.20) 0.262
Min - Max 4-235 4-121
Mean creatinine (SD) mg/l 8.28 (2.39) 8.26 (2.43) 0.924
Min - Max 3-20 4-20
Mean bilirubin (SD) mg/l 9.57 (7.49) 10.88 (11.00) 0.162
Min - Max 2-59 2-85
Mean haemoglobin (SD) g/dl 10.60 (1.81) 10.80 (1.85) 0.289
Min - Max 5.8-15.1 5.1-16.8
* t test for independent samples **Mann-Whitney test § Fisher’s exact test.
Table 2 Proportions of clinical signs at inclusion
Clinical signs DPT N = 206, n (%) AL N = 197, n (%)
Fever 195 (94.7) 182 (92.4)
Headache 164 (79.6) 153 (77.7)
Asthenia 105 (51.0) 103 (52.3)
Anorexia 89 (43.4) 76 (38.6)
Rigors 56 (27.2) 44 (22.4)
Arthralgia 72 (35.0) 69 (35.0)
Abdominal pain 40 (19.4) 56 (28.4)
Pallor 39 (18.9) 39 (19.8)
Splenomegaly 24 (11.7) 12 (6.1)
Vomiting 12 (5.8) 17 (8.6)
Diffuse pain 12 (5.8) 13 (6.6)
Dizziness 6 (2.9) 8 (4.1)
Hepatomegaly 6 (2.9) 3 (1.5)
Nausea 4 (1.94) 2 (1.0)
Jaundice 3 (1.5) 5 (2.5)
Cough 2 (1) 1 (0.5)
Epigastric pain 2 (1) 1 (0.5)
Pruritus 1 (0.5) 0 (0)
Table 3 Distribution by response to treatment in each
arm
DPT n/N
(%)
AL n/N
(%)
ACPR (Adequate Clinical and Parasitological
Response)
204/206
(99)
195/197
(99)
ETF (Early Treatment Failure) 0/206 (0) 1/197 (0.5)
LCF (Late Clinical Failure) 0/206 (0) 1/197 (0.5)
LPF (Late Parasitological Failure) 2/206 (1) 0/197 (0)
Total Failure 2/206 (1) 2/197 (1)
p = 1 Fisher’s exact test.
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malaria. The recovery rates after follow up for 28 days
were 99% for both medicinal products and the lower
limit of the one-sided 97.5% confidence interval of the
rates difference of -1.90%, up to the pre-established non
inferiority margin of -5%, which allows us to confirm
that DPT is not inferior to AL. In addition, abolition of
fever and parasite clearance occurred faster in the DPT
group than in the reference AL group.
However, these high recovery rates could have been
overestimated due to the proportion of subjects over the
age of 15, estimated at approximately 40% of the overall
population of the study. This high proportion of subjects
over the age of 15 in the study population is accounted
for by that fact that many 2-5 year-old children were not
included because one or more signs of severity of their
malarial episode were discovered, whilst very few adults
presented with severe signs. Furthermore, the 28-day
protocol used in this study has limits in identifying cases
of ETT [14].
This result was entirely expected, as the combination
DP (dihydroartemisinin - piperaquine at doses of 20 mg
and 160 mg in children and 40 mg and 320 mg in
adults) had already been shown to have as effective anti-
malarial activity as AL in several African studies [12-16].
Abolition of fever and parasite clearance were similar
for DP and AL [17].
WHO currently recommends treatment with ACT for
at least three days, and the recommended forms of ACT
are only doublet combination therapies. However, the tri-
ple combination therapy suggested in the DPT combina-
tion appears to be an interesting alternative for reducing
treatment time to two days, with excellent therapeutic
efficacy and better parasite and thermal clearance times
than those of AL.
Quadruple therapy, CV8, with a combination of prima-
quine and the three compounds in the studied combina-
tion, DPT, has been shown to offer excellent efficacy and
good tolerability despite the number of associated anti-
malarials [18]. The three compounds in DPT have com-
pletely different mechanisms of action and DPT was as
well tolerated as AL. Whilst in terms of clinical tolerabil-
ity, fewer adverse effects were seen in the AL group, it is
Figure 3 Parasite clearance.
Table 4 Change in individuals’ haemoglobin
concentration by treatment group
Mean haemoglobin concentration in g/dl (standard
deviation)
p*
D1 D7 D1-D7
DPT 10.6 (1.82) 9.9 (1.65) 0.7 (1.38) <0.001
AL 10.8 (1.9) 9.8 (1.8) 1.0 (1.28) < 0.001
P** 0.289 0.570 0.024
*paired t test. ** t test for independent samples
Figure 2 Fever clearance.
Table 5 Incidence of adverse events reported
DPT (N = 206) n (%) AL (N = 197) n (%)
Vomiting* 21 (10.2) 6(3)
Abdominal pain 5 (2.4) 3 (1.5)
Pruritus 6 (3) 2 (1)
Asthenia 2 (1) 5 (2.5)
Nausea 4 (2) 3 (1.5)
Dizziness 1 (0.5) 4 (2)
Epigastric pain 3 (1.5) 0 (0)
Diarrhoea 2 (1) 0 (0)
Skin rash 2(1) 0 (0)
Hypoglycaemia 0 (0) 2(1)
Insomnia 0 (0) 2 (1)
Facial oedema 0 (0) 2 (1)
Drowsiness 2 (1) 0 (0)
Aphthous ulcers 0 (0) 1 (0.5)
Skin fold lesions 0 (0) 1 (0.5)
Rash 1 (0.5) 0 (0)
Productive cough 1 (0.5) 0 (0)
Total 50 31
* p = 0.038, Pearson’s Chi-2 test
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greater with this ACT. All adverse events were minor in
both treatment groups and no treatment-related serious
adverse events were seen.
One of the major benefits of the DPT combination is
the reduction in treatment time, i.e. two days instead of
three. However, the number of daily doses is two as
against a single dose for some ACT such as DP. An
improvement in the pharmaceutical formulation of the
medicine with a view to reducing the number of daily
d o s i n g s ,p a r t i c u l a r l yas i n g l ed o s i n g ,c o u l db eu s e f u lf o r
improved observance of the anti-malarial treatment.
Conclusion
The overall efficacy and tolerability of DPT are similar
to those of AL with the advantage of a shorter treatment
time of two days. The place of DPT in the armamentar-
ium for the treatment of malaria must be further
assessed to increase the efficacy of its use.
List of abbreviations
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